Replay available

Cerus Corporation (CERS) Q2 2025 Earnings Call

Cerus Corporation (NASDAQ: CERS) Q2 2025 earnings conference call, held 2025-08-05. Replay captured from the company's public earnings webcast.

Tue, August 5, 2025 at 4:30 PMendedReplay
Cerus Corporation (CERS) Q2 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Tim Lee

Head of Investor Relations, Cirrus

Obi Greenman

President and Chief Executive Officer

Vivek Jayaraman

Chief Operating Officer

Kevin Green

Chief Financial Officer

Matt Park

Analyst (on for Ross Osborne)

Replay transcript excerpt

Good day, ladies and gentlemen. Thank you for standing by and welcome to the Serious Corporation Second Quarter 2025 Earnings Conference Call. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Tim Lee, Serious Head of Investor Relations. Tim, you may now begin. Thank you and good afternoon. I'd like to thank everyone for joining us today. As part of today's webcast, we are simultaneously displaying slides that you can follow. You can access the slides from the Investor Relations website at ir.cirrus.com. With me on the call are Obi Greenman, Cirrus's President and Chief Executive Officer, Vivek Jayaraman, Cirrus's Chief Operating Officer, Kevin Green, Cirrus' Chief Financial Officer, and Carol Moore, Cirrus' Senior Vice President. Cirrus issued a press release today announcing our financial results for the second quarter ended June 30, 2025, and describing the company's recent business highlights. You can access a copy of this announcement on the company's website at www.cirrus.com. I'd like to remind you that some of the statements we will make on this call relate to future events and performance rather than historical facts and are forward-looking statements. Examples of forward-looking statements include those related to our future financial and operating results, including our 2025 revenue guidance, our expectations for operating cash flow, and non-GAAP adjusted EBITDA performance and our expected expense levels, expected future growth and our growth trajectory, the availability and related timing of data from clinical trials, planned regulatory submissions, product launches, product expansion prospects, and other statements that are not historical fact. These forward-looking statements involve risks and ...

More from Cerus Corporation